Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

303.59 +7.67 (+2.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand To Report Third Quarter 2023 Financial Results On November 8
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Where Ligand Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Expectations for Ligand Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Recap: Ligand Pharmaceuticals Q1 Earnings ↗
 
Via Benzinga
News headline image
Ligand Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Appoints Martine Zimmermann to its Board of Directors
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio... 
Via Benzinga
News headline image
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports Second Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand To Report Second Quarter 2023 Financial Results On August 8
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Why Are Novan Shares Nosediving Today? ↗
Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to  
Via Benzinga
News headline image
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
From Novan, Inc.
Via GlobeNewswire
News headline image
3 Stocks That Smart Investors Should Be Flocking to Now ↗
Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors. 
Via InvestorPlace
News headline image
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial ↗
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
Via Benzinga
News headline image
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports First Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment ↗
 
Via Benzinga
News headline image
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Earnings Scheduled For February 22, 2023 ↗
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
News headline image
Ligand to Report Fourth Quarter Financial Results on February 22
From Ligand Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.